<?xml version="1.0" encoding="UTF-8"?>


<article dtd-version="1.0" article-type="research-article">
  <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">intejhealeconman</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50020182</journal-id>
         <journal-title-group xmlns:xlink="http://www.w3.org/1999/xlink">
            <journal-title>International Journal of Health Economics and Management</journal-title>
         </journal-title-group>
      
         <publisher>
            <publisher-name>Springer</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">21999023</issn>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="epub">21999031</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <volume xmlns:mml="http://www.w3.org/1998/Math/MathML"
                 xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">17</volume>
         <issue xmlns:mml="http://www.w3.org/1998/Math/MathML"
                xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">2</issue>
         <issue-id>i40228036</issue-id>
         <article-id pub-id-type="doi">10.2307/45271487</article-id>
         <article-categories>
            <subj-group>
               <subject>RESEARCH ARTICLE</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Product safety spillovers and market viability for biologic drugs</article-title>
         </title-group>
         <contrib-group>
            <contrib>
               <string-name>
                  <given-names>John</given-names>
                  <surname>Romley</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>Tiffany</given-names>
                  <surname>Shih</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>6</month>
            <year>2017</year>
         </pub-date>
         <fpage>135</fpage>
         <lpage>158</lpage>
      
      
         <permissions>
            <copyright-statement>© Springer Science+Business Media, LLC 2017</copyright-statement>
         </permissions>
         <self-uri xlink:href="https://www.jstor.org/stable/45271487"/>
      
      
         <abstract>
            <p>When a pharmaceutical manufacturer experiences a safety problem, negative impacts on profitability can spread to its competitors. Reduced consumer confidence, product recalls, and litigation are limited to the responsible manufacturer only if that manufacturer can be clearly linked to the safety problem. We analyze the impact of "accountability" for safety problems on manufacturer entry decisions and investments to mitigate risk. Consistent with prior research, we find investment levels increase with accountability in a duopoly market, and that accountability can thus enhance market viability and improve consumer welfare. However, we also analyze the impact of accountability on entry of a competitor, after the originator's exclusivity has expired. Accountability promotes the development of a robust market by raising expected profits, particularly for an entrant with a relatively low likelihood of a safety problem. Yet entry need not improve consumer welfare, and may benefit the incumbent in our model. In contrast to the traditional entry deterrence mechanism, when accountability is sufficiently low, increased incumbent investment encourages entry. Our analysis has important implications for biologic drugs, insofar as pathways for entry by "biosimilars" have been established in Europe and the United States, and informs pharmacovigilance and other accountability policies for biologies.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
  </front>
  <back>
    
      <fn-group xmlns:xlink="http://www.w3.org/1999/xlink">
        <title>[Footnotes]</title>
        <fn id="d675e153a1310">
            <label>1</label>
          
            <p>
               <mixed-citation id="d675e160" publication-type="other">
Graham et al. 2005</mixed-citation>
            </p>
        </fn>
        <fn id="d675e167a1310">
            <label>2</label>
          
            <p>
               <mixed-citation id="d675e174" publication-type="other">
http://blogs.fda.gov/fdavoice/index.php/tag/biological-products/.</mixed-citation>
            </p>
        </fn>
        <fn id="d675e181a1310">
            <label>8</label>
          
            <p>
               <mixed-citation id="d675e188" publication-type="other">
Pirmohamed et al. 2007</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d675e194" publication-type="other">
Siegal 2014;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d675e200" publication-type="other">
Wish 2011</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d675e207" publication-type="other">
Bennett and Yin 2014;</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d675e213" publication-type="other">
Das et al. 2015</mixed-citation>
            </p>
        </fn>
        <fn id="d675e220a1310">
            <label>9</label>
          
            <p>
               <mixed-citation id="d675e227" publication-type="other">
Dimasi et al. 2003</mixed-citation>
            </p>
        </fn>
      </fn-group>
    
    
      <ref-list>
        <title>References</title>
        <ref id="d675e243a1310">
          
            <mixed-citation id="d675e247" publication-type="other">
Akerlof, G. A. (1970). The market for "lemons": Quality uncertainty and the market mechanism. The Quarterly
Journal of Economics, 80, 488-500.</mixed-citation>
        </ref>
        <ref id="d675e257a1310">
          
            <mixed-citation id="d675e261" publication-type="other">
Allen, F. (1984). Reputation and product quality. The RAND Journal of Economics, 15(3), 311-327.</mixed-citation>
        </ref>
        <ref id="d675e268a1310">
          
            <mixed-citation id="d675e272" publication-type="other">
Anderson, S., De Palma, A., &amp; Thisse, J. (1992). Discrete choice theory of product differentiation. New York:
MIT press.</mixed-citation>
        </ref>
        <ref id="d675e282a1310">
          
            <mixed-citation id="d675e286" publication-type="other">
Bennett, D., &amp; Yin, W. (2014). The market for high-quality medicine. No. w20091. National Bureau of
Economic Research.</mixed-citation>
        </ref>
        <ref id="d675e297a1310">
          
            <mixed-citation id="d675e301" publication-type="other">
Berry, S., Levinsohn, J., &amp; Pakes, A. (1995). Automobile prices in market equilibrium. Econometrica: Journal
of the Econometric Society, 63(4), 841-890.</mixed-citation>
        </ref>
        <ref id="d675e311a1310">
          
            <mixed-citation id="d675e315" publication-type="other">
Caplin, A., &amp; Nalebuff, B. (1991). Aggregation and imperfect competition: On the existence of equilibrium.
Econometrica: Journal of the Econometric Society. 59(1), 25-59.</mixed-citation>
        </ref>
        <ref id="d675e325a1310">
          
            <mixed-citation id="d675e329" publication-type="other">
Carriquiry, M., &amp; Babcock, B. A. (2007). Reputations, market structure, and the choice of quality assurance
systems in the food industry. American Journal of Agricultural Economics, 89, 12-23.</mixed-citation>
        </ref>
        <ref id="d675e339a1310">
          
            <mixed-citation id="d675e343" publication-type="other">
Casadevall, N„ Edwards, I. R., Felix, T., Graze, P. R., Linen, J. B., Strober, B. E., et al. (2013). Pharmacovigi-
lance and biosimilars: Considerations, needs and challenges. Expert Opinion on Biological Therapy, 13,
1039-1047.</mixed-citation>
        </ref>
        <ref id="d675e356a1310">
          
            <mixed-citation id="d675e360" publication-type="other">
Cawley, J., &amp; Rizzo, J. A. (2008). Spillover effects of prescription drug withdrawals. Advances in Health
Economics and Health Services Research, 19, 119-144.</mixed-citation>
        </ref>
        <ref id="d675e370a1310">
          
            <mixed-citation id="d675e374" publication-type="other">
Chauhan, D., Towse, A., &amp; Mestre-Ferrandiz, J. (2013). The market for biosimilars: Evolution and policy
options. OHE briefing no. 45, Office of Health Economics, London. 2008.</mixed-citation>
        </ref>
        <ref id="d675e385a1310">
          
            <mixed-citation id="d675e389" publication-type="other">
Collins, J. M.. Simon, K. I., &amp; Tennyson, S. (2013). Drug withdrawals and the utilization of therapeutic
substitutes: The case of Vioxx. Journal of Economic Behavior &amp; Organization, 86, 148-168.</mixed-citation>
        </ref>
        <ref id="d675e399a1310">
          
            <mixed-citation id="d675e403" publication-type="other">
Das. J., Holla, A., Mohpal, A., &amp; Muralidharan, K. (2015). Quality and accountability in healthcare delivery:
Audit-study evidence from primary care in India. No. w21405. National Bureau of Economic Research.</mixed-citation>
        </ref>
        <ref id="d675e413a1310">
          
            <mixed-citation id="d675e417" publication-type="other">
Dimasi, J. A., Hansen, R. W., &amp; Grabowski, H. G. (2003). The price of innovation: New estimates of drug
development costs. Journal of Health Economics, 22, 151-185.</mixed-citation>
        </ref>
        <ref id="d675e427a1310">
          
            <mixed-citation id="d675e431" publication-type="other">
Ellison, G. &amp; Ellison, S. F. (2007). Strategic entry deterrence and the behavior of pharmaceutical incumbents
prior to patent expiration. National Bureau of Economic Research.</mixed-citation>
        </ref>
        <ref id="d675e441a1310">
          
            <mixed-citation id="d675e445" publication-type="other">
Grabowski, H., Cockburn, I., &amp; Long, G. (2006). The market for follow-on biologies: How will it evolve?
Health Affairs, 25, 1291-1301.</mixed-citation>
        </ref>
        <ref id="d675e455a1310">
          
            <mixed-citation id="d675e459" publication-type="other">
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., et al. (2005). Risk of acute myocardial
infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective
non-steroidal anti-inflammatory drugs: Nested case-control study. The Lancet, 365(9458), 475-481.</mixed-citation>
        </ref>
        <ref id="d675e473a1310">
          
            <mixed-citation id="d675e477" publication-type="other">
Hennessy, S., Leonard, C., &amp; Platt, R. (2010). Assessing the safety and comparative effectiveness of follow-on
biologies (biosimilars) in the United States. Clinical Pharmacology &amp; Therapeutics, 87, 157-159.</mixed-citation>
        </ref>
        <ref id="d675e487a1310">
          
            <mixed-citation id="d675e491" publication-type="other">
Immordino, G., Pagano, M., &amp; Polo, M. (2011). Incentives to innovate and social harm: Laissez-faire, autho-
rization or penalties? Journal of Public Economics, 95, 864-876.</mixed-citation>
        </ref>
        <ref id="d675e501a1310">
          
            <mixed-citation id="d675e505" publication-type="other">
Klein, B. &amp; Leffler, K. B. (1981). The role of market forces in assuring contractual performance. The Journal
of Political Economy. 89(A), 615-641.</mixed-citation>
        </ref>
        <ref id="d675e515a1310">
          
            <mixed-citation id="d675e519" publication-type="other">
Kolstad, C. D., Ulen, T. S., &amp; Johnson, G. V. (1990). Ex post liability for harm vs. ex ante safety regulation:
Substitutes or complements? The American Economic Review, 80(4), 888-901.</mixed-citation>
        </ref>
        <ref id="d675e529a1310">
          
            <mixed-citation id="d675e533" publication-type="other">
Lietzan, E., Sim, L. E. &amp; Alexander, E. A. (2013). Biosimilar naming: How do adverse event reporting data
support the need for distinct non -proprietary names for biosimilars? Food and Drug Policy Forum, 3(6).</mixed-citation>
        </ref>
        <ref id="d675e543a1310">
          
            <mixed-citation id="d675e547" publication-type="other">
Marinigli, R., Lane, D. A., &amp; Lip, G. Y. (2011). Severe renal impairment and stroke prevention in atrial
fibrillation: Implications for thromboprophylaxis and bleeding risk. Journal of the American College of
Cardiology, 57, 1339-1348.</mixed-citation>
        </ref>
        <ref id="d675e561a1310">
          
            <mixed-citation id="d675e565" publication-type="other">
Mcquade, T., Salant, S. W. &amp; Winfree, J. (2010). Regulating an experience good in developing countries when
consumers cannot identify producers. Forthcoming in review of development economics.</mixed-citation>
        </ref>
        <ref id="d675e575a1310">
          
            <mixed-citation id="d675e579" publication-type="other">
Philipson, T. J., &amp; Sun, E. (2008). Is the food and drug administration safe and effective? The Journal of
Economic Perspectives, 22, 85-102.</mixed-citation>
        </ref>
        <ref id="d675e589a1310">
          
            <mixed-citation id="d675e593" publication-type="other">
Pirmohamed, M., Atuah, K. N., Dodoo, A. N., &amp; Winstanley, P. (2007). Pharmacovigilance in developing
countries. British Medical Journal, 335, 462-462.</mixed-citation>
        </ref>
        <ref id="d675e603a1310">
          
            <mixed-citation id="d675e607" publication-type="other">
Pouliot, S., &amp; Sumner, D. A. (2008). Traceability, liability, and incentives for food safety and quality. American
Journal of Agricultural Economics, 90, 15-27.</mixed-citation>
        </ref>
        <ref id="d675e617a1310">
          
            <mixed-citation id="d675e621" publication-type="other">
Pouliot, S. &amp; Sumner, D. A. (2012). Traceability, recalls, industry reputation and product safety. European
Review of Agricultural Economics, 43(5), jbs006.</mixed-citation>
        </ref>
        <ref id="d675e631a1310">
          
            <mixed-citation id="d675e635" publication-type="other">
Scott Morton, F. &amp; Kyle, M. (2012) Markets for pharmaceutical products. Handbook of Health Economics,
2(12), 765.</mixed-citation>
        </ref>
        <ref id="d675e646a1310">
          
            <mixed-citation id="d675e650" publication-type="other">
Shapiro, C. (1982). Consumer information, product quality, and seller reputation. The Bell Journal of Eco-
nomics, 13(1), 20-35.</mixed-citation>
        </ref>
        <ref id="d675e660a1310">
          
            <mixed-citation id="d675e664" publication-type="other">
Shapiro, C. (1983). Premiums for high quality products as returns to reputations. The Quarterly Journal of
Economics, 98(4), 659-679.</mixed-citation>
        </ref>
        <ref id="d675e674a1310">
          
            <mixed-citation id="d675e678" publication-type="other">
Siegal, J. P. (January 7 2014). RE: Citizen petition to food and drug administration from the Janssen Pharma-
ceutical Companies of Johnson &amp; Johnson.</mixed-citation>
        </ref>
        <ref id="d675e688a1310">
          
            <mixed-citation id="d675e692" publication-type="other">
Starbird, S. A. (2005). Moral hazard, inspection policy, and food safety. American Journal of Agricultural
Economics, 87, 15-27.</mixed-citation>
        </ref>
        <ref id="d675e702a1310">
          
            <mixed-citation id="d675e706" publication-type="other">
U.S. Food and Drug Administration. (2011). Generic enoxaparin questions and answers [Online].
US Department of Health &amp; Human Services. http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm220037.htm. Accessed 6 Nov 2014.</mixed-citation>
        </ref>
        <ref id="d675e719a1310">
          
            <mixed-citation id="d675e723" publication-type="other">
Wang, B., Gagne, J. J., &amp; Choudhry, N. K. (2012). The epidemiology of drug recalls in the United States.
Archives of Internal Medicine, 172(14), 1110-1111.</mixed-citation>
        </ref>
        <ref id="d675e734a1310">
          
            <mixed-citation id="d675e738" publication-type="other">
Winfree, J. A., &amp; Mccluskey, J. J. (2005). Collective reputation and quality. American Journal of Agricultural
Economics, 87, 206-213.</mixed-citation>
        </ref>
        <ref id="d675e748a1310">
          
            <mixed-citation id="d675e752" publication-type="other">
Wish, J. B. (2011). Erythropoiesis-stimulating agents and pure red-cell aplasia: You can't fool Mother Nature.
Kidney International, 80, 11-13.</mixed-citation>
        </ref>
      </ref-list>
    
  </back>
</article>


